Axi Luowei Keli (阿昔洛韦颗粒)阿昔洛韦颗粒
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 海口市制药厂有限公司Chinese legal name: 海口市制药厂有限公司
主要成分Active Ingredients
- 阿昔洛韦Axi Luowei
药物知识说明
阿昔洛韦是一种在国家药监局注册认定的药品。该药品含有阿昔洛韦-02d70ff8等成分。
该药品关联的活性成分包括：阿昔洛韦Axi Luowei。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：海口市制药厂有限公司Chinese legal name: 海口市制药厂有限公司。
您可以探索含有相同成分的其他药品：阿昔洛韦-02d70ff8成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 阿昔洛韦颗粒) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 阿昔洛韦Axi Luowei.
Manufacturers recorded for this product: 海口市制药厂有限公司Chinese legal name: 海口市制药厂有限公司.
Explore other medicines containing the same ingredient: 阿昔洛韦 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 阿昔洛韦颗粒Recorded Chinese name: 阿昔洛韦颗粒
- 剂型Dosage form: 颗粒剂Granules
- 规格Specification: 0.2g0.2 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 海口市制药厂有限公司Chinese legal name: 海口市制药厂有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20083336
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20083336
Manufacturer
Chinese legal name: 海口市制药厂有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20083336
生产企业
海口市制药厂有限公司(国产)
适应症
1.单纯疱疹病毒感染：用于生殖器疱疹病毒感染初发和复发病例；对反复发作病例本品用作预防。2.带状疱疹：用于免疫功能正常者带状疱疹和免疫缺陷者轻症病例的治疗。3.用于免疫缺陷者水痘的治疗。
用法用量
口服，成人每次一袋，一日5次(白天每4小时1次)，一疗程5-10日或遵医嘱。
不良反应
1.口服给药少见皮肤搔痒，长程给药偶见月经紊乱。2.长期口服本品可引起关节疼痛、腹泻、头痛、恶心、呕吐、晕眩、口渴、白细胞下降、蛋白尿及尿素氮轻度升高(较短程用药为多)。长期用药可出现痤疮和失眠，短程用药可出现食欲减退，但都较少见。以上症状持续存在或明显时，应引起注意。
禁忌
对本品过敏者和孕妇禁用。
注意事项
1.对更昔洛韦过敏者也可能对本品过敏。2.以下情况需考虑用药利弊：脱水或已有肾功能不全者，本品剂量应减少。3.严重免疫功能缺陷者长期或多次应用本品治疗后可能引起单纯疱疹病毒和带状疱疹病毒对本品耐药。如单纯疱疹患者应用阿昔洛韦后皮损不见改善者应测试单纯疱疹病毒对本品的敏感性。4.随访检查：由于生殖器疱疹患者大多易患子宫颈癌，因此患者至少一年应检查一次，以早期发现。5.一旦疱疹症状与体征出现，应尽早给药。6.口服可同时进食，对吸收无明显影响，生殖器复发性疱疹感染以间歇短程疗法给药有效。由于动物实验曾发性疱疹的长程疗法不应超过6个月。口服给药时应给予患者充足的水，防止本品在肾小管内沉淀。7.一次血液透析可使血药浓度减低60%，因此血液透析后应补给一次剂量。
贮藏
避光
规格
0.2g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.